# The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

> **NCT01556841** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 94 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** TroVax®
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01556841
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2019-04-19
- **Final completion:** 2019-04-19
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2019-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01556841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01556841, "The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01556841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*